Evidence map›Paper›PMID 33588752›Full record

ArticleCellular & molecular biology letters2021

Differentiation of two human neuroblastoma cell lines alters SV2 expression patterns.

Emilia Lekholm, Mikaela M Ceder, Erica C Forsberg, Helgi B Schiöth, Robert Fredriksson

Abstract readLetter
In one paragraph

Article in Cellular & molecular biology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Peptidergic Systems and Neuroblastoma.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emilia LekholmFunctional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden. Emilia.Lekholm@farmbio.uu.se.ORCID http://orcid.org/0000-0001-8135-9127
Mikaela M CederMolecular Neuropharmacology, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Erica C ForsbergMolecular Neuropharmacology, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Helgi B SchiöthFunctional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.
Robert FredrikssonMolecular Neuropharmacology, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe synaptic vesicle glycoprotein 2 (SV2) family is essential to the synaptic machinery involved in neurotransmission and vesicle recycling. The isoforms SV2A, SV2B and SV2C are implicated in neurological diseases such as epilepsy, Alzheimer's and Parkinson's disease. Suitable cell systems for studying regulation of these proteins are essential. Here we present gene expression data of SV2A, SV2B and SV2C in two human neuroblastoma cell lines after differentiation.

methodsHuman neuroblastoma cell lines SiMa and IMR-32 were treated for seven days with growth supplements (B-27 and N-2), all-trans-retinoic acid (ATRA) or vasoactive intestinal peptide (VIP) and gene expression levels of SV2 and neuronal targets were analyzed.

resultsThe two cell lines reacted differently to the treatments, and only one of the three SV2 isoforms was affected at a time. SV2B and choline O-acetyltransferase (CHAT) expression was changed in concert after growth supplement treatment, decreasing in SiMa cells while increasing in IMR-32. ATRA treatment resulted in no detected changes in SV2 expression in either cell line while VIP increased both SV2C and dopamine transporter (DAT) in IMR-32 cells.

conclusionThe synergistic expression patterns between SV2B and CHAT as well as between SV2C and DAT mirror the connectivity between these targets found in disease models and knock-out animals, although here no genetic alteration was made. These cell lines and differentiation treatments could possibly be used to study SV2 regulation and function.

Indexed as

Gene Expression Regulation, NeoplasticBinding SitesCell DifferentiationCell Line, TumorHumansMembrane GlycoproteinsNerve Tissue ProteinsNeuroblastomaPromoter Regions, GeneticTranscription FactorsTranscription Initiation SiteTretinoinVasoactive Intestinal PeptideMembrane GlycoproteinsNerve Tissue ProteinsSV2A protein, humanSV2B protein, humanSV2C protein, humanTranscription FactorsTretinoinVasoactive Intestinal PeptideDifferentiationNeuroblastomaSV2ASV2BSV2CSynaptic vesicle protein

Identifiers

PMID33588752
PMCPMC7885392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.